Meitheal Pharmaceuticals (Meitheal) is pleased to announce the official launch of Octreotide Acetate Injection:
- 71288-566-02 – Octreotide Acetate Injection, 50 mcg per mL
- 71288-567-02 – Octreotide Acetate Injection, 100 mcg per mL
- 71288-568-02 – Octreotide Acetate Injection, 500 mcg per mL
ABOUT Octreotide Acetate Injection
Octreotide Acetate Injection is indicated for reducing growth hormone (GH) and insulin growth factor-1 (IGF-1) levels in acromegaly patients unresponsive or intolerant to standard therapies, for the symptomatic treatment of metastatic carcinoid tumors to control severe diarrhea and flushing, and for managing profuse watery diarrhea associated with VIP-secreting tumors.
For full prescribing information, please click on the following link.
Learn more about who we are and what we do at: www.meithealpharma.com.
